PharmAbcine, Inc. (PharmAbcine) is a privately held biotechnology company. It is principally engaged in the research and development of full human therapeutic monoclonal antibody (mAb). The company develops its products for the treatment of cancer and inflammatory diseases based on its innovative discovery technology platform. Its lead product candidate, mAb is under preclinical stage and Bi-specific, a next generation antibody therapeutics is in early stage of research. The company uses its own stem cell library to explore various cancerous molecular markers. In addition, it also out-licenses the candidate therapeutics and clinical application. PharmAbcine was formed as a spin off government-funded research institute, namely, Korea Research Institute of Bioscience and Biotechnology (KRIBB). PharmAbcine is headquartered in Daejeon, Republic of Korea.